title: Selective alpha 1-adrenergic inhibition improves decrease glucose disposal in patients with essential hypertension.
abstract: This study evaluated insulin secretion and insulin sensitivity before and after short-term oral administration of doxazosin in patients with essential hypertension. The hypertensive group consisted of 11 nonobese subjects (aged 41.0 +/- 2.5 years (mean +/- SEM), body mass index 24.0 +/- 0.53 kg/m2). The normotensive group consisted of 12 subjects matched to the hypertensive group for age and body mass index. The hypertensive group showed significantly higher concentrations of prestimulated and stimulated plasma insulin and plasma C peptide than normal groups. The insulin-mediated glucose disposal rate during euglycaemic clamp (M-value) was significantly lower in the hypertensive group than in normal controls (7.32 +/- 0.56 vs 8.88 +/- 0.34 mg/kg/min, P < 0.05). After one month of doxazosin treatment blood pressure was significantly reduced (P < 0.05). The short-term administration of doxazosin improved the M-value significantly to 8.60 +/- 0.62 mg/kg/min without a significant change in stimulated plasma C-peptide level. These data show that hypertension is associated with increased insulin secretion and impaired insulin sensitivity. Selective alpha 1-adrenergic inhibition with doxazosin improves the decreased glucose disposal rate associated with hypertension.
authors.affiliation: First Department of Medicine, Osaka University Medical School, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Yamasaki
authors.forename: Y
authors.initials: Y
authors.lastname: Shiba
authors.forename: M
authors.initials: M
authors.lastname: Sekiya
authors.forename: T
authors.initials: T
authors.lastname: Tsujino
authors.forename: N
authors.initials: N
authors.lastname: Hakui
authors.forename: R
authors.initials: R
authors.lastname: Kawamori
authors.forename: T
authors.initials: T
authors.lastname: Kamada
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001786:Blood Glucose / Q000032:analysis*; D001794:Blood Pressure / Q000187:drug effects; D002096:C-Peptide / Q000097:blood; D016022:Case-Control Studies; D017292:Doxazosin / Q000494:pharmacology*; D005260:Female; D005947:Glucose / Q000494:pharmacology*; D015309:Glucose Clamp Technique; D005951:Glucose Tolerance Test; D006801:Humans; D006973:Hypertension / Q000097:blood*; D007328:Insulin / Q000097:blood / Q000378:metabolism*; D000078790:Insulin Secretion; D008297:Male
chemical_list: D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin; D005947:Glucose; D017292:Doxazosin